Patents by Inventor Tamie J Chilcote
Tamie J Chilcote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240254211Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: January 30, 2024Publication date: August 1, 2024Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
-
Publication number: 20210032318Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: April 7, 2020Publication date: February 4, 2021Applicants: Prothena Biosciences Limited, The Regents of the University of CaliforniaInventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
-
Publication number: 20190300598Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: February 21, 2019Publication date: October 3, 2019Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: DALE B. SCHENK, ELIEZER MASLIAH, MANUEL J. BUTTINI, TAMIE J. CHILCOTE, EDWARD M. ROCKENSTEIN, KATE DORA GAMES
-
Publication number: 20180355028Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.Type: ApplicationFiled: May 16, 2018Publication date: December 13, 2018Inventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
-
Patent number: 9879071Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.Type: GrantFiled: September 5, 2012Date of Patent: January 30, 2018Assignee: Prothena Biosciences LimitedInventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
-
Publication number: 20170349651Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: May 30, 2017Publication date: December 7, 2017Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
-
Publication number: 20170204173Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.Type: ApplicationFiled: March 22, 2017Publication date: July 20, 2017Inventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
-
Patent number: 9034337Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: February 23, 2007Date of Patent: May 19, 2015Assignee: Prothena Biosciences LimitedInventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Patent number: 8506959Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: July 19, 2005Date of Patent: August 13, 2013Assignees: Neotope Biosciences Limited, The Regents of the University of CaliforniaInventors: Dale B. Schenk, Eliezer Masliah, Manuel Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
-
Publication number: 20130072663Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.Type: ApplicationFiled: September 5, 2012Publication date: March 21, 2013Applicant: Elan Pharmaceuticals, Inc.Inventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
-
Publication number: 20120201842Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: February 22, 2012Publication date: August 9, 2012Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ELAN PHARMACEUTICALS, INC.Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Patent number: 8148089Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.Type: GrantFiled: February 8, 2010Date of Patent: April 3, 2012Assignee: Elan Pharma International LimitedInventors: John P. Anderson, Kelly Banducci, Guriqbal S. Basi, David Chereau, Tamie J. Chilcote, Normand L. Frigon, Jr., Jason Goldstein, Irene Griswold
-
Patent number: 8147833Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: February 22, 2008Date of Patent: April 3, 2012Assignees: Neotope Biosciences Limited, The Regents of the University of CaliforniaInventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Patent number: 8092801Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: February 25, 2008Date of Patent: January 10, 2012Assignee: Neotope Biosciences LimitedInventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Publication number: 20110207796Abstract: Agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient are provided. Preferred agents include inhibitors of PLK2 kinase.Type: ApplicationFiled: February 13, 2009Publication date: August 25, 2011Inventors: John P. Anderson, Kelly Banducci, Guriqbal S. Basi, David Chereau, Tamie J. Chilcote, Normand L. Frigon, JR., Jason Goldstein, Irene Griswold-Prenner
-
Patent number: 7919088Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: August 20, 2007Date of Patent: April 5, 2011Assignees: Elan Pharmaceuticals, Inc., The Regents of the University of CaliforniaInventors: Dale B. Schenk, Kate Dora Games, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Eliezar Masliah
-
Publication number: 20100278814Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: February 25, 2008Publication date: November 4, 2010Applicants: ELAN PHARMACEUTICALS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Publication number: 20100143946Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.Type: ApplicationFiled: February 8, 2010Publication date: June 10, 2010Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: JOHN P. ANDERSON, KELLY BANDUCCI, GURIQBAL S. BASI, DAVID CHEREAU, TAMIE J. CHILCOTE, NORMAND L. FRIGON, JR., JASON GOLDSTEIN, IRENE GRISWOLD-PRENNER
-
Publication number: 20100031377Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: August 9, 2005Publication date: February 4, 2010Applicant: ELAN PHARMACEUTICALS, INC.Inventors: Dale B Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Publication number: 20090208487Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: February 23, 2007Publication date: August 20, 2009Applicant: Elan Pharmaceuticals, Inc.Inventors: Dale B. Schenk, Kate Dora Games, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Eliezar Masliah